Xilio Therapeutics annual return on equity
2021
2022
2023
2024
2025
Xilio Therapeutics Return on Equity (ROE) Growth & History (XLO)
Xilio Therapeutics's return on equity was −132.53% for fiscal 2025.
View full Xilio Therapeutics company overviewXilio Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −132.53% | +81.49 pp |
| 2024 | 2024-12-31 | −214.02% | −106.77 pp |
| 2023 | 2023-12-31 | −107.25% | −46.64 pp |
| 2022 | 2022-12-31 | −60.62% | +87.80 pp |
| 2021 | 2021-12-31 | −148.42% | — |
Xilio Therapeutics quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −8.80% | +169.53 pp |
| Q1 2026 | 2026-03-31 | −17.68% | +76.08 pp |
| Q4 2025 | 2025-12-31 | 76.24% | +144.13 pp |
| Q2 2025 | 2025-06-30 | −178.33% | −131.27 pp |
| Q1 2025 | 2025-03-31 | −93.75% | −38.78 pp |
| Q4 2024 | 2024-12-31 | −67.89% | −28.36 pp |
| Q3 2024 | 2024-09-30 | −51.55% | −23.61 pp |
| Q2 2024 | 2024-06-30 | −47.06% | −21.62 pp |
| Q1 2024 | 2024-03-31 | −54.97% | −31.19 pp |
| Q4 2023 | 2023-12-31 | −39.53% | −20.16 pp |
| Q3 2023 | 2023-09-30 | −27.94% | −13.31 pp |
| Q2 2023 | 2023-06-30 | −25.44% | −9.58 pp |
| Q1 2023 | 2023-03-31 | −23.78% | −11.64 pp |
| Q4 2022 | 2022-12-31 | −19.37% | +61.08 pp |
| Q3 2022 | 2022-09-30 | −14.63% | — |
| Q2 2022 | 2022-06-30 | −15.86% | — |
| Q1 2022 | 2022-03-31 | −12.15% | — |
| Q4 2021 | 2021-12-31 | −80.45% | — |
Xilio Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Xilio Therapeutics's return on equity increased from −148.42% to −132.53%, a change of +15.89 percentage points. The latest reported quarter, Q2 2026, shows −8.80%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics source filings ↗